|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib.
|
29731638 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
We used a natural language search program to search our electronic medical record system and every EGFR mutation analysis of patients with NSCLC treated at Mayo Clinic that was performed in our Department of Molecular Genetics to identify patients with EGFR S768I mutation.
|
27211795 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Consistently, afatinib was clinically effective for the treatment of NSCLC harboring G719C and S768I mutations of EGFR.
|
27794398 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib.
|
20522446 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib.
|
20522446 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
|
19536777 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
|
19147750 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
GeneticVariation
|
CLINVAR |
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
|
17653080 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
|
16863509 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
|
16205628 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
|
15623594 |
2004 |
|
Esophageal carcinoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Squamous cell carcinoma of lung
|
|
0.700 |
GeneticVariation
|
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
|
Squamous cell carcinoma of lung
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
|
Esophageal carcinoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Gefitinib-sensitizing mutations in esophageal carcinoma.
|
16707764 |
2006 |
|
Adenocarcinoma of lung (disorder)
|
|
0.050 |
GeneticVariation
|
BEFREE |
Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.
|
29731638 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.050 |
GeneticVariation
|
BEFREE |
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
|
28024692 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
|
0.050 |
GeneticVariation
|
BEFREE |
This study aimed to investigate the prevalence of the S768I mutation in Chinese patients with lung AC and to retrospectively analyze the response of S768I mutants to tyrosine kinase inhibitors (TKIs).
|
27538584 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
|
0.050 |
GeneticVariation
|
BEFREE |
Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.
|
23261230 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.050 |
GeneticVariation
|
BEFREE |
Here, we report the first case of adenocarcinoma of the lung in which the patient had rare mutations S768I and V769L and was treated with gefitinib.
|
17045698 |
2006 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Subanalysis of clinical trials, and real-world data, demonstrate that EGFRs with defined, but uncommon mutations such as G719X, S768I, and L861Q are sensitive to afatinib, which is now approved for tumors harboring these mutations.
|
31558282 |
2019 |
|
Squamous cell carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
|
28024692 |
2017 |
|
Adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
S768I Mutation in EGFR in Patients with Lung Cancer.
|
27211795 |
2016 |